Antibodies: Genentech

Total Score People Score Events Score
38 35 28
Date Event Presentation Speakers
March 1, 2016 2nd Protease Inhibitors in Drug Discovery Conference The Challenge of Finding Inhibitory Antibodies Against the Trimeric Serine Protease HtrA1 for Treatment of Ocular Disease Daniel Kirchhofer
February 10, 2013 7thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE: An Intensive Course on Translating Research into Drugs Antibodies and Immunotherapy for Neurodegeneration Ryan J. Watts
November 29, 2011 The 7th annual European Antibody Congress is the worldleading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development. Effects of molecular properties on antibody pharmacokinetics: recent lessons Saileta Prabhu
February 12, 2011 Cancer Control by Tumor Suppressors and Immune Effectors (J8) Dendritic Cells (J7) | MHC Class II Pathways Ira Mellman
January 13, 2011 Second Annual Protein Aggregation and Emerging Analytical Tools Towards Understanding Ion-Induced Protein Aggregation: Correlation with Biophysical Predictors of Stability Yatin Gokarn
Interactive Panel | Aggregation-Related Manufacturing and Quality Issues Yatin Gokarn
January 13, 2011 Inaugural Antibody Drug Products Drug Conjugation Site Modulates the Stability and Biological Activity of Antibody Drug Conjugates Ben Shen
January 12, 2011 Antibodies for the 21st Century Endogenous Anti-IFNa Autoantibodies in Patients with Systemic Lupus Erythematosus are Associated with Decreased IFN-Pathway and Disease Activity Alyssa Morimoto
January 11, 2011 Fourteenth Annual Choosing, Designing, and Optimizing Hosts and Platforms Triple Light Chain Antibodies: Factors that Influence its Formation in Cell Culture Natalia Gomez
January 10, 2011 Third Annual Optimizing Biologics Formulation Development The Use of Forced Degradation to Optimize Protein Formulation J. Andrea Ji
Early Formulation Screening of Monoclonal Antibodies: Selecting Molecules with Optimal Physical and Chemical Stability Vikas Sharma
January 10, 2011 Third Annual Protein Purification & Recovery New Insights into Parvovirus Filtration for Monoclonal Antibody Purification Amit Mehta
Applying Disposable Applications in Downstream Processing Adam Goldstein
May 20, 2010 Bioanalytical Challenges for Optimizing Protein Therapeutics Free vs. Total Ligand Binding Assays: Points to Consider in Drug Development Jihong Yang
Immunogenicity: Regulatory and Technical Overview with Case Studies of Assay Challenges Eric Wakshull
May 20, 2010 Revival of Bispecific Antibodies: The Way Forward? bis-Fabs: A New Platform for Bispecific Molecules Justin M. Scheer
May 19, 2010 Pre-Clinical / Clinical Development of Therapeutic Antibodies Recommendations for Nonclinical PK Comparability Study Designs for Monoclonal Antibodies Wendy Putnam
May 17, 2010 Phage and Yeast Display of Antibodies and Proteins Chairperson’s Opening Remarks Sachdev Sidhu
May 17, 2010 Immunogenicity of Therapeutic Biologics A Novel Homogeneous Biotin-Digoxigenin Based Assay for the Detection of Human Anti-Therapeutic Antibodies in Autoimmune Serum Julia Qiu
October 26, 2009 Immunogenicity Assessment and Clinical Relevance Challenges with Development of Anti-Therapeutic Antibody Assays to Detect Antibodies of IgE Subtype Sally Fischer
October 6, 2009 Phage Display to Develop Therapeutic Antibodies Synthetic PDZ Domains for Functional Genomics Sachdev Sidhu
Antibody Fragments and Scaffolds Sachdev Sidhu
August 26, 2009 Optimizing Mammalian Cell Lines Development of a Novel Double Selection System to Improve Antibody Productivity in CHO Cell Lines Domingos Ng
August 3, 2009 The Next Wave of Antibody Therapeutics Antibody-Drug Conjugates for Cancer Therapy Paul G. Polakis
Clinical Results of the Phase I and Phase II Studies of Trastuzumab-DM1, A First-in-class HER2 Antibody-Drug Conjugate, in Patients with HER2+ Metastatic Breast Cancer Barbara Klencke
December 7, 2008 Antibody Engineering Highly Functional Minimalist Antibodies Sachdev Sidhu
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Protein Metabolism/catabolism in the Disposition of Protein Therapeutics Paul J. Fielder
Optimizing ADME/PK Properties of Biotherapeutics Lisa Damico
Establishing the First in Human Dose for Biotherapeutics Jennifer E. Visich
April 30, 2008 Assessment of Immunogenicity in Clinical Trials Case Study –Risk-based Immunogenicity Valerie Quarmby
April 28, 2008 Clinical Development of Therapeutic Antibodies The Development of Antiangiogenics in Lung Cancer Jane Huang
April 27, 2008 Phage Display of Antibodies and Peptides Chairperson’s Remarks Dev Sidhu
Synthetic Antibodies Germaine Fuh
April 27, 2008 Phage Display of Antibodies and Peptides Synthetic Antibodies Germaine Fuh
November 12, 2007 Well Characterized Biologicals - Continuous Evolution of Chemo- and Bioanalytical Approaches Nov(12 - 14) Analysis of Protein Glycosylation (10:45-13:25) An Song
Analysis of Protein Glycosylation:Anticipating Effects of Glycosylation on Effector Functions (10:45-11:15) An Song
Causes and Assessment of Product and Process-Related Impurities (13:25-18:30) Fred Jacobson
Causes and Assessment of Product and Process-Related Impurities:Protein Aggregation and Bioprocessing (13:30-14:00) Fred Jacobson
Early Formulation Development (08:15-09:15) Jim Andya
Early Formulation Development: Early Development Screening of Monoclonal Antibody Formulations (08:15-08:45) Jim Andya
Process and Analytical Related Issues (15:30-17:00) Ron Taticek
Process and Analytical Related Issues: Quality by Design in the Development of Post-Approval Changes for Cell Culture Processes (15:30-16:00) Ron Taticek
November 7, 2007 Antibodies Europe: Engineering the Next Generation of Antibodies Nov (07-08) Engineering Therapeutics (10:00-11:30) Robert Kelley
Engineering Therapeutics: Fc Engineering of Therapeutic Antibodies (10:00-10:30) Robert Kelley
August 11, 2007 Growth factor receptor tyrosine kinases in mitogenesis, morphogenesis Signaling specificity of growth factor RTKs (2nd part) Mark Sliwkowski
HER2 activation in breast and ovarian cancers Mark Sliwkowski
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.